Is Galmed Pharmaceuticals Ltd (GLMD) Stock About to Get Hot Wednesday?

Overall market sentiment has been down on Galmed Pharmaceuticals Ltd (GLMD) stock lately. GLMD receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Galmed Pharmaceuticals Ltd has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GLMD!

See Full GLMD Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With GLMD Stock Today?

Galmed Pharmaceuticals Ltd (GLMD) stock is lower by -2.65% while the S&P 500 is up 0.24% as of 2:59 PM on Wednesday, Jul 19. GLMD is down -$0.04 from the previous closing price of $1.32 on volume of 158,212 shares. Over the past year the S&P 500 has risen 19.19% while GLMD is down -85.92%. GLMD lost -$8.08 per share in the over the last 12 months. To screen for more stocks like Galmed Pharmaceuticals Ltd click here.

More About Galmed Pharmaceuticals Ltd

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis. Click Here to get the full Stock Report for Galmed Pharmaceuticals Ltd stock.